Source: CLINVAR

Variant Gene Disease Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs11554290
rs11554290
NRAS
CUI: C0025202
Disease: melanoma
melanoma 		A 0.800 CausalMutation CLINVAR Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 25157968

2014
dbSNP: rs11554290
rs11554290
NRAS
CUI: C0025202
Disease: melanoma
melanoma 		G 0.800 CausalMutation CLINVAR Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 25157968

2014
dbSNP: rs11554290
rs11554290
NRAS
CUI: C0025202
Disease: melanoma
melanoma 		C 0.800 CausalMutation CLINVAR Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 25157968

2014
dbSNP: rs11554290
rs11554290
NRAS
CUI: C0025202
Disease: melanoma
melanoma 		C 0.800 CausalMutation CLINVAR MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. 23414587

2013
dbSNP: rs11554290
rs11554290
NRAS
CUI: C0025202
Disease: melanoma
melanoma 		C 0.800 CausalMutation CLINVAR Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. 23538902

2013
dbSNP: rs11554290
rs11554290
NRAS
CUI: C0025202
Disease: melanoma
melanoma 		C 0.800 CausalMutation CLINVAR Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. 23614898

2013
dbSNP: rs11554290
rs11554290
NRAS
CUI: C0025202
Disease: melanoma
melanoma 		G 0.800 CausalMutation CLINVAR Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. 23538902

2013
dbSNP: rs11554290
rs11554290
NRAS
CUI: C0025202
Disease: melanoma
melanoma 		G 0.800 CausalMutation CLINVAR Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. 23614898

2013
dbSNP: rs11554290
rs11554290
NRAS
CUI: C0025202
Disease: melanoma
melanoma 		A 0.800 CausalMutation CLINVAR Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. 23569304

2013
dbSNP: rs11554290
rs11554290
NRAS
CUI: C0025202
Disease: melanoma
melanoma 		G 0.800 CausalMutation CLINVAR Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. 23569304

2013
dbSNP: rs11554290
rs11554290
NRAS
CUI: C0025202
Disease: melanoma
melanoma 		A 0.800 CausalMutation CLINVAR Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. 23614898

2013
dbSNP: rs11554290
rs11554290
NRAS
CUI: C0025202
Disease: melanoma
melanoma 		A 0.800 CausalMutation CLINVAR MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. 23414587

2013
dbSNP: rs11554290
rs11554290
NRAS
CUI: C0025202
Disease: melanoma
melanoma 		C 0.800 CausalMutation CLINVAR Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. 23569304

2013
dbSNP: rs11554290
rs11554290
NRAS
CUI: C0025202
Disease: melanoma
melanoma 		A 0.800 CausalMutation CLINVAR Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. 23538902

2013
dbSNP: rs11554290
rs11554290
NRAS
CUI: C0025202
Disease: melanoma
melanoma 		G 0.800 CausalMutation CLINVAR MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. 23414587

2013
dbSNP: rs11554290
rs11554290
NRAS
CUI: C0025202
Disease: melanoma
melanoma 		C 0.800 CausalMutation CLINVAR First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. 22761467

2012
dbSNP: rs11554290
rs11554290
NRAS
CUI: C0025202
Disease: melanoma
melanoma 		A 0.800 CausalMutation CLINVAR First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. 22761467

2012
dbSNP: rs11554290
rs11554290
NRAS
CUI: C0025202
Disease: melanoma
melanoma 		G 0.800 CausalMutation CLINVAR First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. 22761467

2012
dbSNP: rs11554290
rs11554290
NRAS
CUI: C0025202
Disease: melanoma
melanoma 		A 0.800 CausalMutation CLINVAR NRAS-mutant melanoma: response to chemotherapy. 21576590

2011
dbSNP: rs11554290
rs11554290
NRAS
CUI: C0025202
Disease: melanoma
melanoma 		C 0.800 CausalMutation CLINVAR NRAS-mutant melanoma: response to chemotherapy. 21576590

2011
dbSNP: rs11554290
rs11554290
NRAS
CUI: C0025202
Disease: melanoma
melanoma 		A 0.800 CausalMutation CLINVAR Furthermore, PLX4032 increased the rate of proliferation of growth factor-dependent NRAS Q61L mutant primary melanoma cells, reduced cell adherence and increased mobility of cells from advanced lesions. 20149136

2010
dbSNP: rs11554290
rs11554290
NRAS
CUI: C0025202
Disease: melanoma
melanoma 		A 0.800 CausalMutation CLINVAR RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. 20130576

2010
dbSNP: rs11554290
rs11554290
NRAS
CUI: C0025202
Disease: melanoma
melanoma 		C 0.800 CausalMutation CLINVAR RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. 20179705

2010
dbSNP: rs11554290
rs11554290
NRAS
CUI: C0025202
Disease: melanoma
melanoma 		G 0.800 CausalMutation CLINVAR RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. 20179705

2010
dbSNP: rs11554290
rs11554290
NRAS
CUI: C0025202
Disease: melanoma
melanoma 		C 0.800 CausalMutation CLINVAR Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. 21107323

2010